Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43839   clinical trials with a EudraCT protocol, of which   7280   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2012-005124-15
    Sponsor's Protocol Code Number:CAMN107AIC05
    National Competent Authority:Germany - BfArM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2013-02-26
    Trial results View results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedGermany - BfArM
    A.2EudraCT number2012-005124-15
    A.3Full title of the trial
    A prospective, randomized, open label two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia chromosome-positive CML after two different durations of consolidation treatment with nilotinib 300mg BID.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A clinical research study evaluating the possibility to suspend the drug nilotinib (Tasigna) in chronic myeloid leukemia (CML) patients who have been for two different durations on Tasigna with a predifined level of molecular response.
    A.3.2Name or abbreviated title of the trial where available
    A.4.1Sponsor's protocol code numberCAMN107AIC05
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT01743989
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorNovartis Pharma Services AG
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportNovartis Pharma Services AG
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationNovartis Pharma GmbH
    B.5.2Functional name of contact pointMedizinischer Infoservice (MCC)
    B.5.3 Address:
    B.5.3.1Street AddressRoonstrasse 25
    B.5.3.2Town/ cityNürnberg
    B.5.3.3Post code90429
    B.5.4Telephone number+491802232300
    B.5.5Fax number+4991127312160
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D. name Tasigna
    D. of the Marketing Authorisation holderNovartis Europharm Limited
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/06/375
    D.3 Description of the IMP
    D.3.1Product namenilotinib
    D.3.2Product code AMN107
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNILOTINIB
    D.3.9.1CAS number 641571-10-0
    D.3.9.2Current sponsor codeAMN107
    D.3.9.4EV Substance CodeSUB25225
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number150
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product No
    D. ATIMP (i.e. one involving a medical device) No
    D. on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Adult patients with Ph+ chronic phase CML that have been treated with Imatinib for at least 2 years, are in CCyR, but have not achieved MR4.0 at study entry.
    E.1.1.1Medical condition in easily understood language
    Adult patients with CML who have been treated with imatinib (Glivec) for at least two years and who have not achieved a certain level of molecular response at study entry.
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10054352
    E.1.2Term Chronic phase chronic myeloid leukemia
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To assess the optimal duration of consolidation treatment with nilotinib 300 mg BID in order that patients remain in TFR (≥MR4.0) without molecular relapse 12 months after entering TFR phase.
    E.2.2Secondary objectives of the trial
    - To evaluate the proportion of patients who are eligible to suspend nilotinib therapy by achieving and maintaining a sustained ≥MR4.0 for at least 12 months during consolidation treatment with nilotinib 300 mg BID.
    - To assess the achievement of MMR, MR4.0, and MR4.5 during induction/consolidation treatment with nilotinib 300 mg BID
    - To assess the molecular response in patients during induction/consolidation treatment with nilotinib 300 mg BID
    - To assess the proportion of patients in TFR at 3, 6, 12, 18 and 24 months after nilotinib cessation
    - To assess the molecular response in patients after randomization
    - To assess the kinetics of BCR-ABL transcript during induction/consolidation treatment with nilotinib 300 mg BID
    - To assess the kinetics of BCR-ABL transcript during the TFR phase
    - To assess the PFS, TFS, OS
    - To assess the safety profile of nilotinib
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Optional Stem cells ENESTPath substudy:
    The Stem cells ENESTPath substudy adds the determination of Ph+ stem cells in bone marrow for those patients consenting to participate in the substudy.
    - To evaluate the presence and number of LSC and their progenitors in the bone marrow of all patients participating in this substudy before and after completing induction and first year of consolidation phase (at Visit 8);
    - To evaluate if prolonging treatment re-initiationperiod of consolidation with nilotinib (patients in Arm 2 versus patients in Arm 1) induces a reduction in the percentage of patients presenting LSC and progenitor cells in bone marrow at the end of the second year of the consolidation phase
    - To perform an exploratory analysis in order to evaluate whether relapse in patients during the TFR phase in either arm correlates with the presence of LSC and progenitor cells in bone marrow at the end of the consolidation phase and at the time of relapse during TFR.

    "CML patients' voice" Italian substudy:
    The "CML patients' voice" Italian substudy will evaluate the emotional aspects in patients participating to a nilotinib Treatment-free remission (TFR) trial. This substudy aims to examine patients' psycho-emotional characteristics, quality of life and experiences of being involved in CAMN107AIC05 trial and its discontinuation using a qualitative- quantitative mixed method. The 'CML patient's voice' Italian substudy will be conducted in Italy only [see Post-text Supplement 1].
    E.3Principal inclusion criteria
    • Male or female patients, aged ≥ 18 years;
    • Eastern Cooperative Oncology Group (ECOG) performance status of 0- 2;
    • Documented confirmed diagnosis of chronic phase Ph+ and/or BCR-ABL+ CML. Documented chronic phase CML must meet all of the following criteria:
    - < 15% blasts in peripheral blood and bone marrow
    - < 30% blasts plus promyelocytes in peripheral blood and bone marrow
    - < 20% basophils in the peripheral blood
    - ≥ 100 x 109/L (≥ 100,000/mm3) platelets
    - No evidence of extramedullary leukemic involvement, with the exception of hepato- and/or splenomegaly
    • Previous first-line treatment with imatinib for a minimum of 24 months (even not continuously) in total and in imatinib treatment at time of enrollment;
    • Patient in CCyR (a patient with MMR is considered to be in CCyR. Therefore, cytogenetic response (CgR) assessment has to be done if a patient has less than MMR in the local laboratory result and/or in the blood sample that was sent to the EUTOS standardized laboratory at the screening visit (patient will be considered screening failure if not in CCyR);
    • Adequate end-organ function
    • Patients must have the following electrolyte values within normal limits at screening analysis, or corrected to within normal limits with supplements prior to the first dose of study medication:
    - Potassium
    - Magnesium
    - Total calcium
    • Patients must have normal marrow function as defined below:
    - Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L.
    - Hemoglobin ≥9.0 g/dL
    - Platelets ≥100 x 109/L
    • Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
    • Written informed consent must be obtained prior to any screening procedures

    For those patients consenting to participate in the optional Stem cells ENESTPath substudy or in the 'CML patient's voice' Italian substudy, the same inclusion criteria for the ENESTPath study will be applicable, plus the following:
    • Separate specific written informed consent for the Stem cells ENESTPath substudy or for the 'CML patient's voice' Italian substudy must be obtained before starting any sub-study related assessment like but not limited to extraction of additional bone marrow samples for stem cells sub-study.
    E.4Principal exclusion criteria
    • Achievement of MR4.0 at study entry;
    • Previous treatment with BCR-ABL inhibitors other than imatinib;
    • Patients with detectable atypical BCR-ABL transcripts defined as absence of typical BCR-ABL transcripts for CML of the types b2(e13)-a2 or b3(e14)-a2 or both simultaneously documented at CML diagnosis or
    at any time before the screening procedure;
    • Previous anticancer agents for CML except for imatinib, and/or cytoreduction after CML diagnosis, and/or interferon for less than 1 year;
    • Known second chronic phase of CML after previous progression to AP/BC
    • Known impaired cardiac function, including the following:
    - Inability to determine the QT interval on ECG
    - Complete left bundle branch block
    - Right bundle branch block plus left anterior or posterior hemiblock
    - Use of a ventricular paced pacemaker
    - Long QT syndrome or a known family history of long QT syndrome
    - History of or presence of clinically significant ventricular or atrial tachyarrhythmias
    - Clinically significant resting bradycardia (<50 beats per minute)
    - QTc >450 msec on the average of three serial baseline ECGs (using the QTcF formula). If QTcF >450msec and electrolytes are not within normal ranges, electrolytes should be corrected and the patient re-tested for the QTc
    - History of clinically documented severe peripheral occlusive disease or severe ischemic cardiovascular disease (e.g. myocardial infarction, ischemic cerebral vascular disease) whenever in the opinion of the investigator other treatments could have a more favorable benefit/risk profile
    - Other clinically significant heart disease (e.g., congestive heart failure or uncontrolled hypertension)
    • Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol;
    • History of acute pancreatitis within 12 months of study entry, or a past medical history of chronic pancreatitis;
    • Known presence of significant congenital or acquired bleeding disorder unrelated to cancer;
    • History of other active malignancies within 5 years prior to study entry with the exception of previous or concomitant basal cell skin cancer, or previous cervical carcinoma in situ treated curatively;
    • Patients who have not recovered from prior surgery;
    • Treatment with other investigational agents within 4 weeks of Day 1;
    • Patients actively receiving therapy with strong CYP3A4 inhibitors and/or inducers or medications that have the potential to prolong the QT interval that cannot be either discontinued or switched to a different medication prior to starting study drug;
    • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug.
    • Patients who are: (a) pregnant, (b) breast feeding, (c) of childbearing potential without a negative pregnancy test prior to baseline and (d) female of childbearing potential unwilling to use highly effective contraceptive precautions (as detailed below) throughout the trial (postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential);
    • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 14 days after the final dose of nilotinib or imatinib. Patients using an oral hormonal contrace
    • Patients not able to understand and comply with study instructions and requirements;
    For those patients consenting to participate in the optional Stem cells ENESTPath substudy or in the 'CML patient's voice' Italian substudy, the same exclusion criteria as for the ENESTPath study will apply.
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoint is the number of patients who remain in TFR (≥ MR4.0) without molecular relapse, at the end of 12 months in the TFR phase of the study, in the nilotinib 12 months consolidation treatment arm versus the nilotinib 24-month consolidation treatment arm.
    Molecular relapse during TFR is defined as the loss of MMR, or the confirmed loss of MR4.0 (defined by 3 consecutive tests less than MR4.0 assessed at 3 consecutive visits according to the visit schedule of the TFR phase)
    E.5.1.1Timepoint(s) of evaluation of this end point
    At the end of 12 months after in the TFR phase
    E.5.2Secondary end point(s)
    - The proportion of patients who achieve a sustained ≥MR4.0 (defined as having 4 out of 5 quarterly assessments of ≥MR4.0 by a (EUTOS) standardized laboratory over the last 12 months and the last assessment before randomization is at least MR4.0) during the consolidation phase of the study.
    - The proportion of patients who achieve MMR, MR4.0, or MR4.5 on the study at selected time points (every 3 months until Month 24 or Month 36 depending on the randomized arm) during the induction/consolidation phase of the study.
    - The proportion of patients who are in MMR, MR4.0, or MR4.5 on the study at selected timepoints (every 3 months until Month 24 or Month 36 depending of the randomized arm) during the induction/consolidation phase of the study.
    - The proportion of patients in TFR, i.e. with no confirmed loss of MR4.0, no loss of MMR and no restarting of nilotinib therapy within the first 3, 6, 12, 18, and 24 months following nilotinib cessation.
    - The proportion of patients who are in MMR, MR4.0, or MR4.5 at selected time points (at Month 3, 6, 12, and every 3 months thereafter until Month 24 or Month 36 depending on the randomized arm) during the TFR phase in each one of the two treatment arms.
    - BCR-ABL transcript levels (IS) during the induction/consolidation phase
    - BCR-ABL transcript levels (IS) during the TFR phase
    - BCR-ABL transcript levels (IS) during the nilotinib re-treatment phase
    - PFS is defined as progression to AP/BC or death from any cause, where the "failure" event is the earliest occurrence of either of these events.
    - TFS is defined as lack of any of the following events: loss of MMR, confirmed loss of MR4.0, re-start of nilotinib treatment for any reason, progression to AP/BC, or death from any cause.
    - Overall survival is defined as the time from randomization to the time of death due to any cause.
    - Safety will be monitored through assessment of Adverse Events, laboratory data, ECG, vital signs.

    The following endpoints are applicable to all the objectives detailed for the optional Stem cells ENESTPath substudy:
    - Proportion of patients with presence of Ph+ LSC in bone marrow (CD34+/CD38+ progenitor cells, CD34+/CD38− stem cells, and CD34+/CD56+ aberrant stem cells [the last ones only if detectable]) at screening and at Visit 8.
    - Proportion of patients with presence of Ph+ LSC in bone marrow (CD34+/CD38+ progenitor cells, CD34+/CD38− stem cells, and CD34+/CD56+ aberrant stem cells [the last ones only if detectable]) at the end of consolidation arm (Visit 8 for Arm 1 and Visit 204 for Arm 2).
    - Proportion of patients with or without molecular relapse in the first year of TFR in either arm by presence of LSC in bone marrow (CD34+/CD38+progenitor cells, CD34+/CD38− stem cells, and CD34+/CD56+ aberrant
    stem cells [the last ones only if detectable]) at Visit 8 and at the time of relapse during TFR.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Please see section 3 of the protocol; secondary endpoints.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    evaluation of treatment free remission rate
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned37
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA251
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years7
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 400
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 165
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state125
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 440
    F.4.2.2In the whole clinical trial 565
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Patients will be treated with Standard of Care.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2013-03-27
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2013-05-16
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2020-07-08
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands